Abstract:
This study aimed to prepare a nanosuspension formulation as a vehicle for the improvement of the ocular delivery of Prednisolone acetate. A high-pressure homogenization technique was used to produce nanosuspensions. Five formulations were prepared using different concentrations of surfactants Pluronic and evaluated for pH, particle size, drug content, differential scanning calorimetry (DSC), X-ray diffractometry (XRD), drug release, drug permeation, and stability. Also, the HET-CAM test was used to evaluate the irritation of eyes by formulations as an alternative to the draize eye test. Optimised formulations showed a small mean size that is well suited for ocular application. Drug content is good with sustained release of the drug. Sterility testing reveals suitability for ocular administration. CAM test demonstrated non-irritancy of ophthalmic nanosuspension. There were no appreciable changes in appearance, mean particle size, PDI, and pH after three months of stability testing. It was concluded that the use of Pluronic F 68 in the formulations does not show eye irritation and could be useful to achieve a suitable nanosuspension of PA as a novel ocular delivery system.

Keywords: Nanosuspension, Pluronic F68, Prednisolone Acetate.